A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Official Title

A Phase 1/2, Multicentre, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Summary:

This is an open-label, multicentre, Phase 1/2 study to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Trial Description

Primary Outcome:

• Dose-limiting Toxicities (DLT)
• Adverse Events (AEs)
• Overall response rate (ORR)

• Time-to-response (TTR)
• Duration of response (DOR)
• Complete Response (CR) rate
• Very good partial response (VGPR) rate

View this trial on ClinicalTrials.gov